Review



cd69 polyclonal antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Proteintech cd69 polyclonal antibody
    Validation cohort for predicting the risk signature of DLBCL survival based on the discovery cohort. (A) Expression of <t>CD69</t> on infiltrating CD8 + T cells in DLBCL (400X). CD69 (red), CD8 (green), DAPI (blue). (B) Kaplan–Meier curves of OS in DLBCL patients with CD69 + /CD8 + and CD69 + /CD8 + . Cases were classified as CD69 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD69. (C) Expression of CD70 on infiltrating CD8 + T cells in DLBCL (400X). CD70 (green), CD8 (red), DAPI (blue). (D) Kaplan–Meier curves of OS in DLBCL patients with CD70 + /CD8 + and CD70 + /CD8 + . Cases were classified as CD70 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD70. (E) The Kaplan-Meier OS curve of the validation cohort (this work. (n=66)) patients between low risk group (n=34) and high risk group (n=32). This work samples were stratified by risk score. (F) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in this work. (G) The Kaplan-Meier OS curve of the validation cohort ( GSE181063 (n=773)) patients between low risk group (n=387) and high risk group (n=386). GSE181063 samples were stratified by risk score. (H) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE181063 . (I) The Kaplan-Meier OS curve of the validation cohort ( GSE117556 (n=469)) patients between low risk group (n=235) and high risk group (n=234). GSE117556 samples were stratified by risk score. (J) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE117556 . Log-rank tests were used to derive p-values for comparisons between two groups.
    Cd69 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 22 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd69 polyclonal antibody/product/Proteintech
    Average 94 stars, based on 22 article reviews
    cd69 polyclonal antibody - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Single-cell and bulk transcriptomics reveal a CD8 + T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma"

    Article Title: Single-cell and bulk transcriptomics reveal a CD8 + T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2025.1685541

    Validation cohort for predicting the risk signature of DLBCL survival based on the discovery cohort. (A) Expression of CD69 on infiltrating CD8 + T cells in DLBCL (400X). CD69 (red), CD8 (green), DAPI (blue). (B) Kaplan–Meier curves of OS in DLBCL patients with CD69 + /CD8 + and CD69 + /CD8 + . Cases were classified as CD69 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD69. (C) Expression of CD70 on infiltrating CD8 + T cells in DLBCL (400X). CD70 (green), CD8 (red), DAPI (blue). (D) Kaplan–Meier curves of OS in DLBCL patients with CD70 + /CD8 + and CD70 + /CD8 + . Cases were classified as CD70 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD70. (E) The Kaplan-Meier OS curve of the validation cohort (this work. (n=66)) patients between low risk group (n=34) and high risk group (n=32). This work samples were stratified by risk score. (F) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in this work. (G) The Kaplan-Meier OS curve of the validation cohort ( GSE181063 (n=773)) patients between low risk group (n=387) and high risk group (n=386). GSE181063 samples were stratified by risk score. (H) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE181063 . (I) The Kaplan-Meier OS curve of the validation cohort ( GSE117556 (n=469)) patients between low risk group (n=235) and high risk group (n=234). GSE117556 samples were stratified by risk score. (J) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE117556 . Log-rank tests were used to derive p-values for comparisons between two groups.
    Figure Legend Snippet: Validation cohort for predicting the risk signature of DLBCL survival based on the discovery cohort. (A) Expression of CD69 on infiltrating CD8 + T cells in DLBCL (400X). CD69 (red), CD8 (green), DAPI (blue). (B) Kaplan–Meier curves of OS in DLBCL patients with CD69 + /CD8 + and CD69 + /CD8 + . Cases were classified as CD69 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD69. (C) Expression of CD70 on infiltrating CD8 + T cells in DLBCL (400X). CD70 (green), CD8 (red), DAPI (blue). (D) Kaplan–Meier curves of OS in DLBCL patients with CD70 + /CD8 + and CD70 + /CD8 + . Cases were classified as CD70 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD70. (E) The Kaplan-Meier OS curve of the validation cohort (this work. (n=66)) patients between low risk group (n=34) and high risk group (n=32). This work samples were stratified by risk score. (F) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in this work. (G) The Kaplan-Meier OS curve of the validation cohort ( GSE181063 (n=773)) patients between low risk group (n=387) and high risk group (n=386). GSE181063 samples were stratified by risk score. (H) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE181063 . (I) The Kaplan-Meier OS curve of the validation cohort ( GSE117556 (n=469)) patients between low risk group (n=235) and high risk group (n=234). GSE117556 samples were stratified by risk score. (J) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE117556 . Log-rank tests were used to derive p-values for comparisons between two groups.

    Techniques Used: Biomarker Discovery, Expressing



    Similar Products

    cd69  (Bioss)
    94
    Bioss cd69
    Cd69, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd69/product/Bioss
    Average 94 stars, based on 1 article reviews
    cd69 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    Proteintech cd69 polyclonal antibody
    Validation cohort for predicting the risk signature of DLBCL survival based on the discovery cohort. (A) Expression of <t>CD69</t> on infiltrating CD8 + T cells in DLBCL (400X). CD69 (red), CD8 (green), DAPI (blue). (B) Kaplan–Meier curves of OS in DLBCL patients with CD69 + /CD8 + and CD69 + /CD8 + . Cases were classified as CD69 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD69. (C) Expression of CD70 on infiltrating CD8 + T cells in DLBCL (400X). CD70 (green), CD8 (red), DAPI (blue). (D) Kaplan–Meier curves of OS in DLBCL patients with CD70 + /CD8 + and CD70 + /CD8 + . Cases were classified as CD70 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD70. (E) The Kaplan-Meier OS curve of the validation cohort (this work. (n=66)) patients between low risk group (n=34) and high risk group (n=32). This work samples were stratified by risk score. (F) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in this work. (G) The Kaplan-Meier OS curve of the validation cohort ( GSE181063 (n=773)) patients between low risk group (n=387) and high risk group (n=386). GSE181063 samples were stratified by risk score. (H) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE181063 . (I) The Kaplan-Meier OS curve of the validation cohort ( GSE117556 (n=469)) patients between low risk group (n=235) and high risk group (n=234). GSE117556 samples were stratified by risk score. (J) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE117556 . Log-rank tests were used to derive p-values for comparisons between two groups.
    Cd69 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd69 polyclonal antibody/product/Proteintech
    Average 94 stars, based on 1 article reviews
    cd69 polyclonal antibody - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    Proteintech rabbit polyclonal anti cd69
    Validation cohort for predicting the risk signature of DLBCL survival based on the discovery cohort. (A) Expression of <t>CD69</t> on infiltrating CD8 + T cells in DLBCL (400X). CD69 (red), CD8 (green), DAPI (blue). (B) Kaplan–Meier curves of OS in DLBCL patients with CD69 + /CD8 + and CD69 + /CD8 + . Cases were classified as CD69 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD69. (C) Expression of CD70 on infiltrating CD8 + T cells in DLBCL (400X). CD70 (green), CD8 (red), DAPI (blue). (D) Kaplan–Meier curves of OS in DLBCL patients with CD70 + /CD8 + and CD70 + /CD8 + . Cases were classified as CD70 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD70. (E) The Kaplan-Meier OS curve of the validation cohort (this work. (n=66)) patients between low risk group (n=34) and high risk group (n=32). This work samples were stratified by risk score. (F) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in this work. (G) The Kaplan-Meier OS curve of the validation cohort ( GSE181063 (n=773)) patients between low risk group (n=387) and high risk group (n=386). GSE181063 samples were stratified by risk score. (H) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE181063 . (I) The Kaplan-Meier OS curve of the validation cohort ( GSE117556 (n=469)) patients between low risk group (n=235) and high risk group (n=234). GSE117556 samples were stratified by risk score. (J) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE117556 . Log-rank tests were used to derive p-values for comparisons between two groups.
    Rabbit Polyclonal Anti Cd69, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit polyclonal anti cd69/product/Proteintech
    Average 94 stars, based on 1 article reviews
    rabbit polyclonal anti cd69 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    93
    Bioss differentiation 69
    Validation cohort for predicting the risk signature of DLBCL survival based on the discovery cohort. (A) Expression of <t>CD69</t> on infiltrating CD8 + T cells in DLBCL (400X). CD69 (red), CD8 (green), DAPI (blue). (B) Kaplan–Meier curves of OS in DLBCL patients with CD69 + /CD8 + and CD69 + /CD8 + . Cases were classified as CD69 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD69. (C) Expression of CD70 on infiltrating CD8 + T cells in DLBCL (400X). CD70 (green), CD8 (red), DAPI (blue). (D) Kaplan–Meier curves of OS in DLBCL patients with CD70 + /CD8 + and CD70 + /CD8 + . Cases were classified as CD70 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD70. (E) The Kaplan-Meier OS curve of the validation cohort (this work. (n=66)) patients between low risk group (n=34) and high risk group (n=32). This work samples were stratified by risk score. (F) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in this work. (G) The Kaplan-Meier OS curve of the validation cohort ( GSE181063 (n=773)) patients between low risk group (n=387) and high risk group (n=386). GSE181063 samples were stratified by risk score. (H) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE181063 . (I) The Kaplan-Meier OS curve of the validation cohort ( GSE117556 (n=469)) patients between low risk group (n=235) and high risk group (n=234). GSE117556 samples were stratified by risk score. (J) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE117556 . Log-rank tests were used to derive p-values for comparisons between two groups.
    Differentiation 69, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/differentiation 69/product/Bioss
    Average 93 stars, based on 1 article reviews
    differentiation 69 - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    94
    Bioss primary antibody cd69
    The activation of NK pathway in the EE group. (A–B) KEGG pathway for both up- and downregulated genes. (C) IHC staining was used to detect the expression of <t>CD69.</t> (D) The quantitative analysis of CD69 was performed with ImageJ software. (E–G) q-PCR detected the mRNA expression of NK receptors (H60, RAET, ULBP). n = 5, each group. * p < 0.05, t test. SE: standard environment; EE: environmental enrichment; RAET1: retinoic acid early transcript 1; ULBP1: UL16 binding protein 1.
    Primary Antibody Cd69, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody cd69/product/Bioss
    Average 94 stars, based on 1 article reviews
    primary antibody cd69 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    90
    Thermo Fisher polyclonal antibody cd69 thermofisher #bs-2499r
    The activation of NK pathway in the EE group. (A–B) KEGG pathway for both up- and downregulated genes. (C) IHC staining was used to detect the expression of <t>CD69.</t> (D) The quantitative analysis of CD69 was performed with ImageJ software. (E–G) q-PCR detected the mRNA expression of NK receptors (H60, RAET, ULBP). n = 5, each group. * p < 0.05, t test. SE: standard environment; EE: environmental enrichment; RAET1: retinoic acid early transcript 1; ULBP1: UL16 binding protein 1.
    Polyclonal Antibody Cd69 Thermofisher #Bs 2499r, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal antibody cd69 thermofisher #bs-2499r/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    polyclonal antibody cd69 thermofisher #bs-2499r - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    91
    Atlas Antibodies hpa050525 atlas antibodies cd103 polyclonal
    The activation of NK pathway in the EE group. (A–B) KEGG pathway for both up- and downregulated genes. (C) IHC staining was used to detect the expression of <t>CD69.</t> (D) The quantitative analysis of CD69 was performed with ImageJ software. (E–G) q-PCR detected the mRNA expression of NK receptors (H60, RAET, ULBP). n = 5, each group. * p < 0.05, t test. SE: standard environment; EE: environmental enrichment; RAET1: retinoic acid early transcript 1; ULBP1: UL16 binding protein 1.
    Hpa050525 Atlas Antibodies Cd103 Polyclonal, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hpa050525 atlas antibodies cd103 polyclonal/product/Atlas Antibodies
    Average 91 stars, based on 1 article reviews
    hpa050525 atlas antibodies cd103 polyclonal - by Bioz Stars, 2026-02
    91/100 stars
      Buy from Supplier

    Image Search Results


    Validation cohort for predicting the risk signature of DLBCL survival based on the discovery cohort. (A) Expression of CD69 on infiltrating CD8 + T cells in DLBCL (400X). CD69 (red), CD8 (green), DAPI (blue). (B) Kaplan–Meier curves of OS in DLBCL patients with CD69 + /CD8 + and CD69 + /CD8 + . Cases were classified as CD69 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD69. (C) Expression of CD70 on infiltrating CD8 + T cells in DLBCL (400X). CD70 (green), CD8 (red), DAPI (blue). (D) Kaplan–Meier curves of OS in DLBCL patients with CD70 + /CD8 + and CD70 + /CD8 + . Cases were classified as CD70 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD70. (E) The Kaplan-Meier OS curve of the validation cohort (this work. (n=66)) patients between low risk group (n=34) and high risk group (n=32). This work samples were stratified by risk score. (F) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in this work. (G) The Kaplan-Meier OS curve of the validation cohort ( GSE181063 (n=773)) patients between low risk group (n=387) and high risk group (n=386). GSE181063 samples were stratified by risk score. (H) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE181063 . (I) The Kaplan-Meier OS curve of the validation cohort ( GSE117556 (n=469)) patients between low risk group (n=235) and high risk group (n=234). GSE117556 samples were stratified by risk score. (J) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE117556 . Log-rank tests were used to derive p-values for comparisons between two groups.

    Journal: Frontiers in Immunology

    Article Title: Single-cell and bulk transcriptomics reveal a CD8 + T-cell gene signature predicting prognosis in diffuse large B-cell lymphoma

    doi: 10.3389/fimmu.2025.1685541

    Figure Lengend Snippet: Validation cohort for predicting the risk signature of DLBCL survival based on the discovery cohort. (A) Expression of CD69 on infiltrating CD8 + T cells in DLBCL (400X). CD69 (red), CD8 (green), DAPI (blue). (B) Kaplan–Meier curves of OS in DLBCL patients with CD69 + /CD8 + and CD69 + /CD8 + . Cases were classified as CD69 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD69. (C) Expression of CD70 on infiltrating CD8 + T cells in DLBCL (400X). CD70 (green), CD8 (red), DAPI (blue). (D) Kaplan–Meier curves of OS in DLBCL patients with CD70 + /CD8 + and CD70 + /CD8 + . Cases were classified as CD70 + /CD8 + when ≥10% of infiltrating CD8 + T cells expressed CD70. (E) The Kaplan-Meier OS curve of the validation cohort (this work. (n=66)) patients between low risk group (n=34) and high risk group (n=32). This work samples were stratified by risk score. (F) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in this work. (G) The Kaplan-Meier OS curve of the validation cohort ( GSE181063 (n=773)) patients between low risk group (n=387) and high risk group (n=386). GSE181063 samples were stratified by risk score. (H) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE181063 . (I) The Kaplan-Meier OS curve of the validation cohort ( GSE117556 (n=469)) patients between low risk group (n=235) and high risk group (n=234). GSE117556 samples were stratified by risk score. (J) Univariate Cox regression analysis of Risk Score: high risk, IPI: low-mid, IPI: mid-high and IPI: high in GSE117556 . Log-rank tests were used to derive p-values for comparisons between two groups.

    Article Snippet: The primary antibodies are as follows: CD69 Polyclonal antibody (Proteintech, 10803-1-AP), CD70 Monoclonal antibody (Proteintech, 67749-1-Ig), CD8a Monoclonal antibody (Proteintech, 66868-1-Ig), Anti-CD8 alpha antibody (Abcam, ab93278).

    Techniques: Biomarker Discovery, Expressing

    The activation of NK pathway in the EE group. (A–B) KEGG pathway for both up- and downregulated genes. (C) IHC staining was used to detect the expression of CD69. (D) The quantitative analysis of CD69 was performed with ImageJ software. (E–G) q-PCR detected the mRNA expression of NK receptors (H60, RAET, ULBP). n = 5, each group. * p < 0.05, t test. SE: standard environment; EE: environmental enrichment; RAET1: retinoic acid early transcript 1; ULBP1: UL16 binding protein 1.

    Journal: Environment & Health

    Article Title: Environmental Enrichment Exposure Alleviates Geriatric Depressive-Like Symptoms through Regulating Neurogenesis and Neuroinflammation

    doi: 10.1021/envhealth.4c00186

    Figure Lengend Snippet: The activation of NK pathway in the EE group. (A–B) KEGG pathway for both up- and downregulated genes. (C) IHC staining was used to detect the expression of CD69. (D) The quantitative analysis of CD69 was performed with ImageJ software. (E–G) q-PCR detected the mRNA expression of NK receptors (H60, RAET, ULBP). n = 5, each group. * p < 0.05, t test. SE: standard environment; EE: environmental enrichment; RAET1: retinoic acid early transcript 1; ULBP1: UL16 binding protein 1.

    Article Snippet: The protocol was similar to the IF staining: (1) dewax brain paraffin sections (4 μm) with water; (2) repair antigen and freshen with PBS for 5 min; (3) seal with 5% goat serum for 50 min; (4) add primary antibody CD69 (bs-2499R, Bioss, diluted with 1:200) overnight at 4 °C and wash with PBS for 5 min; (5) add HRP labeled goat antirabbit secondary antibody (GB23303, Servicebio, diluted with 1:200); (6) restain nuclei with DAPI for 10 min; (7) quench tissue autofluorescence; (8) seal sheet.

    Techniques: Activation Assay, Immunohistochemistry, Expressing, Software, Binding Assay